Table 4.

Study outcomes for phase 2 trial

Outcome	Dextromethorphan- bupropion (n = 43)	Bupropion (n = 37)	Difference
Overall change from baseline in MADRS total scorea	−13.7 ± 0.6	−8.8 ± 0.7	−4.9 (−3.1, −6.8)d,*
Change from baseline in MADRS total score, week 2	−12.5 ± 1.4	−7.8 ± 1.5	−4.7 (−0.6, −8.8)d,*
Change from baseline in MADRS total score, week 6	−17.3 ± 1.4	−12.1 ± 1.5	−5.2 (−1.1, −9.3)d,*
Remission at week 2b	11 (25.6)	1 (2.7)	22.9 (8.8, 36.9)e,*
Remission at week 6	20 (46.5)	6 (16.2)	30.3 (11.2, 49.4)e,*
Clinical response at week 2c	16 (37.2)	10 (27.0)	10.2 (−10.2, 30.5)e
Clinical response at week 6	26 (60.5)	15 (40.5)	19.9 (−1.6, 41.5)e

Values are presented as least-squares mean ± standard error or number (%).

^aMADRS: Montgomery-Åsberg Depression Rating Scale; 10-item clinician-rated questionnaire with scores ranging from 0−60. A higher score corresponds to more severe depression. ^bRemission defined as MADRS total score ≤ 10. ^cClinical response defined as ≥ 50% reduction in MADRS total score from baseline. ^dLeast-squares mean (95% confidence interval). ^e% (95% confidence interval).

*p < 0.05.